Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.46 |
| ▸ | GAA | P10253 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NQO1 | P15559 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4250447 | 0.79 | CA12 (0.39) | KDM4EALDH1A1MAPTKMT2ANPC1 | |
| SCHEMBL3988877 | 0.77 | GAA (0.57) | KDM4EGAAALDH1A1MAPTKMT2A | |
| SCHEMBL5960702 | 0.77 | SLC22A12 (0.40) | KDM4EGAAALDH1A1MAPTKMT2A | |
| SCHEMBL5694518 | 0.76 | KDM4E (0.45) | KDM4EALDH1A1MAPTKMT2ANPC1 | |
| SCHEMBL11883140 | 0.76 | CA12 (0.37) | KDM4EALDH1A1MAPTKMT2ANPC1 | |
| SCHEMBL4430343 | 0.75 | EYA3 (0.44) | KDM4EGAAALDH1A1MAPTKMT2A | |
| SCHEMBL7192591 | 0.73 | GAA (0.57) | KDM4EGAAALDH1A1MAPTKMT2A | |
| SCHEMBL13948285 | 0.73 | PTPN1 (0.53) | KDM4EGAAALDH1A1MAPTKMT2A | |
| SCHEMBL11881929 | 0.72 | MGAM (0.35) | KDM4EGAAALDH1A1MAPTKMT2A | |
| SCHEMBL9605230 | 0.72 | EYA3 (0.43) | ALDH1A1MAPTKMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183199-A1 | 2-AMINOINDANE COMPOUNDS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC. (US) | 2023-06-15 | — | — | US | disclosed |
| EP-4192447-A1 | 2-AMINOINDANE COMPOUNDS FOR MENTAL DISORDERS OR ENHANCEMENT | Tactogen Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-116209657-A | 2-aminoindane compounds for mental disorders or enhancement | 泰科根公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-116075300-A | Advantageous benzofuran compositions for mental disorders or mental enhancement | 泰科根公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-2108649-B1 | Novel indol carboxylic acid bispyridyl carboxamide derivatives as 5-HT2c receptor antagonists | KOREA RES INST CHEM TECH (KR) | 2013-04-24 | — | — | EP | disclosed |
| US-8324246-B2 | Indol carboxylic acid bispyridyl carboxamide derivatives, pharmaceutically acceptable salt thereof, preparation method and composition containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-04 | — | — | US | disclosed |
| EP-1335907-B1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB PUBL (SE) | 2010-06-09 | — | — | EP | disclosed |
| EP-1513831-B1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB PUBL (SE) | 2010-01-06 | — | — | EP | disclosed |
| US-20090258876-A1 | NOVEL INDOL CARBOXYLIC ACID BISPYRIDYL CARBOXAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD AND COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-10-15 | — | — | US | disclosed |
| WO-2009125923-A2 | NOVEL INDOL CARBOXYLIC ACID BISPYRIDYL CARBOXAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD AND COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-10-15 | — | — | WO | disclosed |
| WO-2003000663-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| US-20020147200-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-10-10 | — | — | US | disclosed |
| US-20020103204-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-08-01 | — | — | US | disclosed |
| WO-2002040456-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002040457-A1 | PIPERAZINYLPYRAZINES COMPOUNDS AS ANTAGONISTS OF SEROTONIN 5-HT2 RECEPTOR | BIOVITRUM AB (SE) | 2002-05-23 | — | — | WO | disclosed |
| EP-1149085-A1 | AMINOALKYLBENZOFURANS AS SEROTONIN (5-HT(2C)) AGONISTS | ELI LILLY AND COMPANY (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-1149085-A1 | AMINOALKYLBENZOFURANS AS SEROTONIN (5-HT(2C)) AGONISTS | ELI LILLY AND COMPANY (US) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000044737-A1 | AMINOALKYLBENZOFURANS AS SEROTONIN (5-HT(2C)) AGONISTS | ELI LILLY AND COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000044737-A1 | AMINOALKYLBENZOFURANS AS SEROTONIN (5-HT(2C)) AGONISTS | ELI LILLY AND COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-0029311-B1 | AMINOALKYL BENZOFURAN DERIVATIVES, THEIR PRODUCTION AND COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1985-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183199-A1 | 2-AMINOINDANE COMPOUNDS FOR MENTAL DISORDERS OR ENHANCEMENT | AADAT, SLC1A2, TPH2 | KDM4E 3126/4885GAA 3415/4885ALDH1A1 643/4885 |
| US-20020103204-A1 | Novel compounds and their use | HTR2C, HTR1A, HTR1B | KDM4E 2610/4885GAA 4690/4885ALDH1A1 500/4885 |
| US-20090258876-A1 | NOVEL INDOL CARBOXYLIC ACID BISPYRIDYL CARBOXAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD AND COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | HTR2C, HTR5A, HTR2A | KDM4E 1130/4885GAA 3399/4885ALDH1A1 1218/4885 |
| US-20020147200-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | KDM4E 1971/4885GAA 844/4885ALDH1A1 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.